bisbenzimidazole trihydrochloride has been researched along with vorinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Du, J; Fang, H; Hou, X; Li, X; Liu, M; Yang, X; Zhang, J; Zhao, H | 1 |
| Chen, C; Chu, H; Gao, Y; Han, L; Li, W; Liu, S; Wang, A; Yin, H | 1 |
2 other study(ies) available for bisbenzimidazole trihydrochloride and vorinostat
| Article | Year |
|---|---|
Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; DNA; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunotherapy; Macrophages; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Docking Simulation; Neoplasms; T-Lymphocytes; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2022 |
Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
Topics: Antineoplastic Agents; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Hydroxamic Acids; Structure-Activity Relationship; Thiadiazoles | 2022 |